NCT01714544已完成4 期
An Open-Label, Multicenter Study of the Efficacy of Cloderm® Cream (Clocortolone Pivalate, 0.1%) in the Treatment of Moderate Plaque Psoriasis for 28 Days
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 60
- 试验地点
- 5
- 主要终点
- Investigator's Global Assessment (IGA)
研究概览
简要总结
The purpose of this study is to determine whether Cloderm Cream is effective for topical treatment of moderate psoriasis over 28 days.
详细描述
The objective of this study is to estimate the efficacy of Cloderm Cream for topical treatment of moderate plaque psoriasis over 28 days using current standards for evaluation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject understands the study procedures and agrees to participate by giving written informed consent.
- •Subjects must be at least 18 years of age.
- •Subjects must present with a clinical diagnosis of stable (at least 3 months) plaque-type psoriasis.
- •Subjects with psoriasis involving 2 to 20% BSA, not including the face, scalp and intertriginous areas.
- •Subjects must have an IGA Grade of 3 at the Baseline Visit.
- •Female subjects of childbearing potential must have a negative urine pregnancy test result at Baseline (Visit 2) (test will have a sensitivity of at least 25mIU/ml for human chorionic gonadotropin) and practice a reliable method of contraception or remain sexually inactive throughout the study.
- •All women of childbearing potential must be willing to undergo a urine pregnancy test at Visit 2 (Day 0), at Visit 4 (Day 14), and at Visit 5 (Day 28).
- •Subjects must be in good general health as determined by the investigator and supported by the medical history and normal or not clinically significant abnormal vital signs (blood pressure and pulse).
排除标准
- •Current diagnosis of unstable forms of psoriasis including guttate, erythrodermic, exfoliative or pustular psoriasis.
- •Other inflammatory skin disease that may confound the evaluation of the plaque psoriasis (e.g., atopic dermatitis, contact dermatitis, tinea corporis).
- •Presence of pigmentation, extensive scarring, pigmented lesions or sunburn which could interfere with the rating of efficacy parameters.
- •History of psoriasis unresponsive to topical treatments.
- •History of organ transplant requiring immunosuppression, HIV, or other immunocompromised state.
- •Use within 180 days prior to Baseline Visit of biologic treatment for psoriasis (e.g., infliximab, adalimumab, etanercept, ustekinumab, or alefacept).
- •Have received treatment for any type of cancer within 5 years of the Baseline Visit except for non-melanoma skin cancer and cervical cancer (in situ) are allowed within 1 year of the Baseline Visit.
- •Use within 60 days prior to the Baseline Visit of: 1) immunosuppressive drugs (e.g., tacrolimus, pimecrolimus), 2) systemic antipsoriatic treatment (e.g., methotrexate, cyclosporine, hydroxyurea) or 3) oral retinoids (e.g., acitretin, isotretinoin).
- •Use within 30 days prior to the Baseline Visit of: 1) systemic steroids, 2) PUVA therapy, 3) systemic anti-inflammatory agents (e.g., mycophenolate mofetil, sulfasalazine, 6-thioguanine), or 4) UVB therapy. Note: Inhaled, intraocular and intranasal steroids are allowed.
- •Use within 14 days prior to the Baseline Visit of: 1) topical antipsoriatic drugs (e.g., salicylic acid, anthralin, coal tar, calcipotriene), 2) topical retinoids (e.g., tazarotene, tretinoin) or 3) topical corticosteroids.
- •Subjects with known hypersensitivity to clocortolone pivalate or any component of Cloderm Cream.
- •Subjects who have participated in a study of an investigational drug 60 days prior to the Baseline Visit.
- •Subjects unable to comply with study requirements.
- •Female subjects who are pregnant (or planning to become pregnant) or breast-feeding.
研究组 & 干预措施
Cloderm Cream
Experimental
Cloderm (clocortolone pivalate) Cream 0.1%, twice daily for 28 days
干预措施: Cloderm Cream (Drug)
结局指标
主要结局
Investigator's Global Assessment (IGA)
时间窗: 28 days
The proportion of subjects who demonstrate an IGA score of clear (0) or almost clear (1).
次要结局
未报告次要终点
研究者
研究点 (5)
Loading locations...
相似试验
已完成
2 期
Cromoglicate in PsoriasisPsoriasisNCT01722812LEO Pharma30
已完成
3 期
Topical Antifungal Treatment for Tinea PedisTinea PedisNCT01396811Medicis Global Service Corporation322
已完成
3 期
Topical Antifungal Treatment for Tinea PedisTinea PedisNCT01396785Medicis Global Service Corporation321
招募中
3 期
Efficacy and Safety of Clascoterone Cream 1% in Facial Acne VulgarisAcne VulgarisNCT06403501Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.692
已完成
4 期
Efficacy and Safety of Therapy With Tri-Luma® Cream in Sequence With Glycolic Acid Peels for MelasmaMelasmaNCT00472966Galderma R&D20